Clinical trials recruiting for Pancreatic cancer
870
Recruiting trials
51
US states with sites
57
Countries
8%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Gemcitabine | 52 |
| Nab-paclitaxel | 41 |
| Pembrolizumab | 17 |
| Irinotecan | 13 |
| Oxaliplatin | 13 |
| mFOLFIRINOX | 13 |
| Fluorouracil | 11 |
| Cetuximab | 10 |
| Cisplatin | 9 |
| Cyclophosphamide | 9 |
| Leucovorin | 9 |
| Bevacizumab | 8 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 150 |
| Texas | 142 |
| New York | 115 |
| Florida | 108 |
| Massachusetts | 83 |
| Ohio | 79 |
| Tennessee | 77 |
| Pennsylvania | 70 |
| Michigan | 67 |
| Virginia | 66 |
| North Carolina | 59 |
| Maryland | 58 |
Top cities
Houston, Texas 102New York, New York 99Boston, Massachusetts 79Los Angeles, California 66Nashville, Tennessee 66San Antonio, Texas 55Fairfax, Virginia 52St Louis, Missouri 47Philadelphia, Pennsylvania 44Chicago, Illinois 42
Self-screener
Recruiting trials
- 18F-DOPA II - PET Imaging Optimization
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
- 68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors
- 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
- A 2-part Phase 1/2 Open-label Trial on ODM-212
- A Beta-only IL-2 ImmunoTherapY Study
- A Brief Psychological Intervention to Improve Emotional Well-Being During Neoadjuvant Therapy for Pancreatic Cancer
- A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET
- A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type)
- A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
- A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
- A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
- A Clinicobiological Database in Metastatic Digestive Cancers
- A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer
- A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma
- A First-in-Human Study of FID-022 in Solid Tumor Patients
- A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
- A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- A IIT Study of 177Lu-DOTA-SNA040
- A Liquid Biopsy for Pancreatic Cancer Early-detection and Disease Monitoring
- A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
- A New Clinical Pathway for Personalized Management of Borderline Resectable and Locally Advanced Pancreatic Cancer
- A New Strategy for Preoperative Drainage of Resectable Pancreatic Head Cancer Combined Severe Obstructive Jaundice
- A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
- A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
- A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
- A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
- A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
- A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
- A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer
- A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
- A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
- A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
- A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors
- A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
- A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors
- A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
- A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
- A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
- A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
- A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
- A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer
- A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
- A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
- A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
- A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain
- A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
- A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
- A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer
- A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer
- A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer
- A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
- A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
- A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
- A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- A Study of DEG6498 in Participants With Solid Tumors
- A Study of DM002 in Patients With Advanced Solid Tumors
- A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer
- A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
- A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
- A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
- A Study of GC203 TIL in PDCA (RJ)
- A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
- A Study of GV20-0251 in Advanced or Refractory Solid Tumors
- A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
- A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment
- A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- A Study of JMT203 in Patients With Cancer Cachexia
- A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- A Study of MGC026 in Participants With Advanced Solid Tumors
- A Study of MGC028 in Participants With Advanced Solid Tumors
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Related conditions
Trials recruiting for Pancreatic cancer often also study these conditions. Each links to its own recruiting-trial list.
Colorectal cancer 1359Lung cancer 2180Breast cancer 2239Pancreas Cancer 86Pancreatic Ductal Adenocarcinoma 64Prostate cancer 1234Gastric cancer 91Ovarian cancer 118Melanoma 487Pancreatic Adenocarcinoma 49
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Pancreatic cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.